Diagnostics & Informatics
The current state
as ofDiagnostics & Informatics in 2026 is shifting from a hardware-and-test-volume business toward integrated platforms that combine assays, instruments, software, automation, and clinical data workflows. The strategic center of gravity is moving to specialty molecular testing, AI-enabled interpretation, decentralized care delivery, and interoperable informatics, while reimbursement pressure, regulatory complexity, and procurement-driven pricing compression are raising the bar for scale and differentiation.
What’s shaping Diagnostics & Informatics right now
- Reimbursement and procurement pressure is squeezing routine testing economics, pushing vendors toward specialty assays, software revenue, and demonstrable clinical utility.
- Regulatory and market-access complexity increasingly favors scaled incumbents that can fund validation, quality systems, cybersecurity, and multi-jurisdiction compliance.
- Care decentralization is moving testing from central labs to point-of-care, home, and remote settings, reshaping product design and distribution models.
- Precision medicine demand is expanding molecular diagnostics, companion diagnostics, and liquid biopsy as oncology and chronic disease management become more biomarker-driven.
- Interoperability requirements are making EHR, LIS, imaging, and lab-data connectivity a competitive necessity rather than a back-office integration task.
Dynamics on the rise and in decline
Rising
Platform consolidation
Diagnostics vendors and healthcare IT firms are increasingly bundling end-to-end capabilities across instruments, assays, LIS/LIMS, analytics, and workflow software, accelerating consolidation.
Two-speed pricing
Commoditized core testing is seeing margin compression from payer pressure and volume-based procurement, while regulated AI and specialty molecular tests keep premium pricing, widening the pricing gap.
Shift to recurring software
Value capture is moving from one-time instrument placement to recurring software, broader assay menus, and interpretation layers, increasing the importance of integrated ecosystem strategies.
This week’s brief
Earlier briefs
View all →- Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercializationAugust 31, 2026
- Workflow interoperability, integrated diagnostics, and embedded governance reshape AI control pointsAugust 24, 2026
- Workflow-specific AI clears first, companion diagnostics gain reimbursed access, and multiomics shifts to deploymentAugust 17, 2026
- Embedded Clinical Workflows, Commercial Validation Infrastructure, and Cloud Teleradiology OrchestrationAugust 10, 2026
- Infrastructure wins in diagnostics, AI embeds in workflows, and serial testing drives oncology revenueAugust 3, 2026
- Reimbursement and validation reshape diagnostics value, AI diagnostics enter regulated territoryJuly 27, 2026
Tracked trends
View all →- IVDR Audit Bottlenecks — IVDR enforcement is shifting European IVD competition from product claims to audit capacity, documentation quality, and certification readiness.
- Narrow AI Clearances — TCS’s ADD™ AgentHub shows how regulated life sciences workflows are evolving from manual oversight to embedded, AI-driven governance and automation.
- Multiomics Automation — Regulatory wins and automated workflows are making multiomics practical for serial screening, neuro testing, and longitudinal care.
- Platform Monetization — Diagnostics are becoming embedded control systems that steer care pathways, not just generate results.
Deep dive
- What macro forces are shaping diagnostics and informatics in 2026?
- Diagnostics and informatics in 2026 are being shaped by cost pressure, tighter reimbursement and regulation, and continued demand from chronic, infectious, and preventive testing. The industry is also shifting toward decentralized care, with more point-of-care, home, and remote testing supported by telehealth and digital workflows. AI, automation, molecular diagnostics, liquid biopsy, and companion diagnostics are becoming more central as providers seek faster interpretation, higher throughput, and more personalized care. Interoperability, data integration, and supply-chain and geopolitical risk are also important forces influencing product strategy and market access.
- What major developments have reshaped diagnostics and informatics recently?
- In the past six months, diagnostics and informatics have been reshaped by AI moving from pilot projects into validated clinical use, with stronger evidence for lesion detection, pathology analysis, and cross-site model performance. Blood-based Alzheimer’s testing has also advanced, expanding access to earlier and less invasive diagnosis beyond specialty centers. At the same time, molecular diagnostics has continued to scale through lower-cost whole genome sequencing, liquid biopsy investment, and broader NGS commercialization. Digital pathology, lab automation, and AI-enabled software are also consolidating into more integrated platforms, while multiplex infectious disease testing remains an active area of operational improvement.
- What are the key market dynamics in diagnostics and informatics in 2026?
- In 2026, diagnostics and informatics are being shaped by continued consolidation, especially through M&A and platform aggregation, as larger vendors strengthen their positions. Pricing is under pressure in commoditized testing and procurement-driven markets, while premium pricing persists for AI-enabled, interoperable, and highly differentiated solutions. New entrants are coming from startups and adjacent technology firms, but incumbents still benefit from scale, regulatory approvals, and installed customer bases. The value chain is shifting from standalone instruments and tests toward integrated software, workflow automation, assay expansion, and ecosystem-based offerings.
- How is diagnostics and informatics changing in 2026?
- In 2026, diagnostics and informatics are being reshaped by AI-native workflows, multimodal data integration, automation, and more connected digital infrastructure. Labs and imaging teams are using AI for image interpretation, decision support, workflow optimization, and computational pathology, while foundation models combine imaging, EHR, lab, and genomic data to improve diagnostic context. Growth is also coming from point-of-care and at-home testing, wearables, molecular diagnostics, and microfluidic lab-on-a-chip platforms that move testing closer to patients. As diagnostics becomes more distributed and data-rich, interoperability, real-time data exchange, and informatics layers are becoming central to the value chain.
- Who are the leading players in diagnostics and informatics today?
- The diagnostics and informatics market is led by large platform incumbents such as Thermo Fisher Scientific, Danaher, Roche Diagnostics, Abbott, Siemens Healthineers, GE HealthCare, and bioMérieux, along with major lab and clinical informatics vendors like Epic, Oracle/Cerner, Sunquest, CliniSys, and LabWare. Challengers include Quest Diagnostics, Exact Sciences, IDEXX Laboratories, Eurofins Scientific, Revvity, Bruker, QuidelOrtho, Natera, Philips, Agfa-Gevaert, Mach7 Technologies, and Tempus, which compete through scale, specialization, or AI-enabled workflows. Emerging players are concentrated in digital pathology, AI diagnostics, and point-of-care tools, with companies such as Digital Diagnostics, HeartFlow, Butterfly Network, Qure.ai, Niramai, Imagen Technologies, and Zebra Medical Vision gaining attention. Overall, the market is splitting between broad integrated incumbents and newer specialists focused on software, automation, and AI-driven diagnostic applications.
- What developments signal major shifts in diagnostics and informatics?
- Major shifts in diagnostics and informatics are developments that change how tests are performed, how data is managed, and how clinical decisions are made. Examples include AI-driven interpretation, interoperable cloud platforms, liquid biopsy and other molecular diagnostics, and point-of-care or at-home testing that moves diagnostics closer to the patient. Automation and robotics also matter when they materially improve throughput, turnaround time, or staffing efficiency. By contrast, routine noise usually consists of incremental product updates, isolated pilots, or partnership announcements that do not clearly change workflow, adoption, or clinical utility.